StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Strong Q2 beat, raised 2026 guidance, and a meaningful strategic asset through Soleno bolster revenue visibility and optionality; near-term appreciation potential from investors pricing in improved growth and pipeline catalysts.
What happened, with direct paths to the underlying reporting
Neurocrine Biosciences reported a strong Q2 2026, with total revenue of $959M, up 39% year over year, and INGREZZA delivering $716M in net product sales (+15%). The May 2026 Soleno Therapeutics acquisition closed, adding VYKAT XR (54M in Q2; pro forma full quarter $94M). The company increased full-year INGREZZA guidance to $2.825–$2.875B and highlighted 2027 Phase 3 milestones for osavampator and direclidine, signaling a higher growth trajectory next year and into mid-decade. Net impact: higher near-term revenue visibility, longer-term pipeline optionality, and a larger late-stage portfolio.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.